stockportfolio.pro
Stocks / PACS vs XENE
PACS vs XENE
PACS Group, Inc. and Xenon Pharmaceuticals Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| PACS Group, Inc. (PACS) | Xenon Pharmaceuticals Inc. (XENE) | |
|---|---|---|
| Market cap | $5.5B | $5.0B |
| Revenue (latest FY) | $5.29B | $7.50M |
| Net income (latest FY) | $191.54M | $-345.91M |
| Revenue growth (5y CAGR) | 29.7% | -25.3% |
| Net margin | 3.6% | -4612.1% |
| Return on equity | 20.2% | -59.5% |
| P/E ratio | 22.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PACS — free Open XENE — freeFrequently asked questions
Which is bigger, PACS or XENE?
PACS Group, Inc. is larger by market capitalization — $5.5B versus $5.0B.
Which grows faster, PACS or XENE?
Over the last five fiscal years, PACS Group, Inc. grew revenue faster — 29.7%/yr versus -25.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.